A pivotal study of ZL-1310 in second-line extensive stage small cell lung cancer
Latest Information Update: 26 May 2025
At a glance
- Drugs ZL 1310 (Primary)
- Indications Small cell lung cancer
- Focus Registrational; Therapeutic Use
Most Recent Events
- 19 May 2025 According to Zai Lab media release, company remain on track to initiate a pivotal study in small cell lung cancer later this year, positioning us for a potential accelerated approval in 2027.
- 15 May 2025 New trial record
- 08 May 2025 According to Zai Lab media release, company plans to initiate a pivotal study in the second half of 2025.